Supportive Care in Cancer

, Volume 27, Issue 4, pp 1163–1170 | Cite as

Predictive factors for cancer-associated thrombosis in a large retrospective single-center study

  • J. Haltout
  • A. Awada
  • M. Paesmans
  • M. Moreau
  • J. Klastersky
  • G. Machiels
  • M. Ignatiadis
  • N. KoteckiEmail author
Review Article



The relationship between cancer and thrombosis has been studied for years, but reliable guidelines for thromboprophylaxis in that situation are still unclear.


We retrospectively reviewed the files of 3159 consecutive patients with newly diagnosed solid tumors at Jules Bordet Institute from January 2008 to December 2011. Among them, 99 developed a symptomatic thromboembolic episode and were matched with 2 controls (nested case control). The aim was to identify risk factors of thromboembolic events and to validate in our setting the Khorana score.


In the cohort study, nodal status ≥ 2, presence of metastases, and primary tumor site were found to be the most significant predictive factors of a thromboembolic event (n = 99; 3.1%) in the multivariate analysis. In the nested study (n = 265), hemoglobin < 13 g/dL or treatment with a red cell growth factor, CRP ≥ 31.6 mg/L, creatinine level > 0.96 mg/dL, chronic inflammatory disease, and personal or familial history of thromboembolic events were found to be the most significant predictive factors of a thromboembolic event in the multivariate analysis. In our population, the sensitivity, specificity, positive predictive value, and negative predictive value of the Khorana score were respectively 29%, 93%, 15%, and 96%.


We confirm the value of the risk factors identified in the literature with the additional presence of nodal involvement, elevated CRP, and creatinine levels, which may be helpful for patient risk stratification and should be considered in future clinical trials. Our results also suggest that the Khorana score might help to identify patients who can safely be spared of thromboprophylaxis.


Venous thromboembolic events Thromboprophylaxis Cancer Cohort study Risk factors 



The authors acknowledge the contribution of Ornella Martini for English-language editing of this manuscript.

Compliance with ethical standards

The study was approved by Jules Bordet Institute Ethics Committee.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 160(6):809–815CrossRefPubMedGoogle Scholar
  2. 2.
    Falanga A, Panova-Noeva M, Russo L (2009) Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol. 22(1):49–60CrossRefPubMedGoogle Scholar
  3. 3.
    De Cicco M (2004) The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 50(3):187–196CrossRefPubMedGoogle Scholar
  4. 4.
    Farge-Bancel D, Florea L, Bosquet L, Debourdeau P (2008) Treatment of venous thromboembolic disease in cancer patients. Pathol Biol (Paris) 56(4):220–228CrossRefGoogle Scholar
  5. 5.
    Connors JM (2014) Prophylaxis against venous thromboembolism in ambulatory patients with cancer. N Engl J Med. 370(26):2515-9Google Scholar
  6. 6.
    Khorana AA (2010) Venous thromboembolism and prognosis in cancer. Thromb Res. 125(6):490–493CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA et al (2016) International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 17(10):e452–e466CrossRefPubMedGoogle Scholar
  8. 8.
    Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP et al (2013) Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol. 31(17):2189–2204CrossRefGoogle Scholar
  9. 9.
    Di Nisio M, Carrier M, Lyman GH, Khorana AA (2014) Subcommittee on Haemostasis and Malignancy. Prevention of venous thromboembolism in hospitalized medical cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost JTH. 12(10):1746–1749CrossRefPubMedGoogle Scholar
  10. 10.
    Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA et al (2012) Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 141(2 Suppl):e195S–e226SCrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 111(10):4902–4907CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Khorana AA, Connolly GC (2009 Oct 10) Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol Off J Am Soc Clin Oncol. 27(29):4839–4847CrossRefGoogle Scholar
  13. 13.
    Richardson DB (2004) An incidence density sampling program for nested case-control analyses. Occup Environ Med. 61(12):e59CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Lyman GH, Eckert L, Wang Y, Wang H, Cohen A (2013) Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. The Oncologist. 18(12):1321–1329CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Blom JW, Vanderschoot JPM, Oostindiër MJ, Osanto S, van der Meer FJM, Rosendaal FR (2006) Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost JTH. 4(3):529–535CrossRefPubMedGoogle Scholar
  16. 16.
    Blom JW, Doggen CJM, Osanto S, Rosendaal FR (2005) 419 Malignancies, prothrombotic mutations, and the risk of venous 420 thrombosis. JAMA. 293(6):715–722Google Scholar
  17. 17.
    Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 110(10):2339–2346CrossRefPubMedGoogle Scholar
  18. 18.
    Kröger K, Weiland D, Ose C, Neumann N, Weiss S, Hirsch C et al (2006) Risk factors for venous thromboembolic events in cancer patients. Ann Oncol Off J Eur Soc Med Oncol. 17(2):297–303CrossRefGoogle Scholar
  19. 19.
    Bucek RA, Reiter M, Quehenberger P, Minar E (2002) C-reactive protein in the diagnosis of deep vein thrombosis. Br J Haematol. 119(2):385–389CrossRefPubMedGoogle Scholar
  20. 20.
    Fox EA, Kahn SR (2005) The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost. 94(2):362–365PubMedGoogle Scholar
  21. 21.
    Lu H-Y, Liao K-M (2018) Increased risk of deep vein thrombosis in end-stage renal disease patients. BMC Nephrol [Internet].Google Scholar
  22. 22.
    Cheung KL, Bouchard BA, Cushman M (2018) Venous thromboembolism, factor VIII and chronic kidney disease. Thromb Res. 170:10–19CrossRefPubMedGoogle Scholar
  23. 23.
    Mansfield AS, Tafur AJ, Wang CE, Kourelis TV, Wysokinska EM, Yang P (2016) Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. J Thromb Haemost JTH. 14(9):1773–1778CrossRefPubMedGoogle Scholar
  24. 24.
    Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R (2012) A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 7(3):291–292CrossRefPubMedGoogle Scholar
  25. 25.
    Kuderer NM, Culakova E, Lyman GH, Francis C, Falanga A, 383 Khorana AA (2016) Avalidated risk score for venous thromboem- 384 bolism is predictive of cancer progression and mortality. The 385 Oncologist. 21(7):861–867Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Service de Médecine - Urgences, CHU Saint-PierreUniversité Libre de BruxellesBrusselsBelgium
  2. 2.Medical Oncology Clinic, Institut Jules BordetUniversité Libre de BruxellesBrusselsBelgium
  3. 3.Data Center, Institut Jules BordetUniversité Libre de BruxellesBrusselsBelgium

Personalised recommendations